Upstream / Downstream

Explore pathways related to this product.

Antibody Guarantee

CST Antibody Performance Guarantee

LEARN MORE  

To Purchase # 12256S

12256S 300 µl (3 nmol) $249.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY
H

Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-), SignalSilence® c-Raf siRNA I (+), or SignalSilence® c-Raf siRNA II #12342 (+), using c-Raf Antibody #9422 (upper) or GAPDH (D16H11) XP® Rabbit mAb #5174 (lower). The c-Raf Antibody confirms silencing of c-Raf expression, while the GAPDH (D16H11) XP® Rabbit mAb is used as a loading control.

Learn more about how we got this image
Image

Order Details

Custom Ordering Details: This item is packaged to order. Please allow two to three days for your order to be processed and shipped.

Product Usage Information

CST recommends transfection with 100 nM SignalSilence® c-Raf siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.


Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

Product Description

SignalSilence® c-Raf siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit c-Raf expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.


Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

A-Raf, B-Raf, and c-Raf (Raf-1) are the main effectors recruited by GTP-bound Ras to activate the MEK-MAP kinase pathway (1). Activation of c-Raf is the best understood and involves phosphorylation at multiple activating sites including Ser338, Tyr341, Thr491, Ser494, Ser497, and Ser499 (2). p21-activated protein kinase (PAK) has been shown to phosphorylate c-Raf at Ser338 and the Src family phosphorylates Tyr341 to induce c-Raf activity (3,4). Ser338 of c-Raf corresponds to similar sites in A-Raf (Ser299) and B-Raf (Ser445), although this site is constitutively phosphorylated in B-Raf (5). Inhibitory 14-3-3 binding sites on c-Raf (Ser259 and Ser621) can be phosphorylated by Akt and AMPK, respectively (6,7). While A-Raf, B-Raf, and c-Raf are similar in sequence and function, differential regulation has been observed (8). Of particular interest, B-Raf contains three consensus Akt phosphorylation sites (Ser364, Ser428, and Thr439) and lacks a site equivalent to Tyr341 of c-Raf (8,9). Research studies have shown that the B-Raf mutation V600E results in elevated kinase activity and is commonly found in malignant melanoma (10). Six residues of c-Raf (Ser29, Ser43, Ser289, Ser296, Ser301, and Ser642) become hyperphosphorylated in a manner consistent with c-Raf inactivation. The hyperphosphorylation of these six sites is dependent on downstream MEK signaling and renders c-Raf unresponsive to subsequent activation events (11).


1.  Avruch, J. et al. (1994) Trends Biochem Sci 19, 279-83.

2.  Chong, H. et al. (2001) EMBO J 20, 3716-27.

3.  King, A.J. et al. (1998) Nature 396, 180-3.

4.  Fabian, J.R. et al. (1993) Mol Cell Biol 13, 7170-9.

5.  Mason, C.S. et al. (1999) EMBO J 18, 2137-48.

6.  Sprenkle, A.B. et al. (1997) FEBS Lett 403, 254-8.

7.  Marais, R. et al. (1997) J Biol Chem 272, 4378-83.

8.  Zimmermann, S. and Moelling, K. (1999) Science 286, 1741-4.

9.  Guan, K.L. et al. (2000) J Biol Chem 275, 27354-9.

10.  Davies, H. et al. (2002) Nature 417, 949-54.

11.  Dougherty, M.K. et al. (2005) Mol Cell 17, 215-24.


Entrez-Gene Id 5894
Swiss-Prot Acc. P04049


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.